Structural basis of mutant-selectivity and drug-resistance related to CO-1686.
Yan, X.E., Zhu, S.J., Liang, L., Zhao, P., Choi, H.G., Yun, C.H.(2017) Oncotarget 8: 53508-53517
- PubMed: 28881827 
- DOI: 10.18632/oncotarget.18588
- Primary Citation of Related Structures:  
5XDK, 5XDL - PubMed Abstract: 
Non-small-cell lung cancers (NSCLCs) caused by activating mutations in the kinase domain of epidermal growth factor receptor (EGFR) initially respond to first-generation reversible drugs gefitinib and erlotinib. However, clinical efficacy is limited due to the development of drug-resistance that in more than half of the cases are driven by the secondary T790M mutation ...